Investment Holding Companies

ASPIRE BIOPHARMA HOLDINGS INC C/WTS 14/02/2030 (TO PUR COM)

Movano

Brand Engagement Network

Direct Digital

CN Energy

Tryhard

UY SCUTI ACQUISITION CORP COM USD0.0001(S/R) 03/03/2030

Q/C Tech

BlackRock Corporate High Yield Fund, Inc.

EquipmentShare.com

SCWorx

The "Wood Sister" team believes that the five major innovation platforms centered around artificial intelligence are accelerating their integration, which will trigger a leap in global economic growth by the end of this decade. It is expected that the global real GDP growth rate will reach 7.3% by 2030, and the market value of innovative assets will expand from $5 trillion to $28 trillion. Investment in AI infrastructure will increase from $500 billion to $1.4 trillion, with fields such as autonomous driving, AI drug development, and humanoid robots entering large-scale deployment

- ARK Invest's latest report, "Big Ideas 2026," emphasizes a period labeled "The Great Acceleration," identifying 13 innovative fields driven by the fusion of key technologies, primarily artificial intelligence.  
- The report forecasts a significant GDP growth rate of 7.3% by 2030, propelled by innovative assets' market share increasing from 20% to 50%, alongside a surge in data center investment.  
- Notably, it posits that AI will act as a central dynamo, catalyzing various technology trends and reshaping industries, although it cautions that not all emerging technologies will be disruptive.

Wallstreetcn

Invesco Semiconductors ETF

ARK Autonomous Tech & Robotics ETF

Ark Innovation ETF

First Trust S-Network Future Vehicles & Tech ETF

Direxion Semicon Bull 3X

SmartETFs Smart Transportation & Tech ETF

iShares Semiconductor ETF

VanEck Semiconductor ETF

Proshares Ultra Nasdaq Biotech

ISHRS S&P Glb It

SPDR S&P Biotech

Ark Genomic Revolution ETF

ARK Next Gen Internet ETF

"Wood Sister" Annual Heavyweight: ARK 2026 Big Idea

The experience of the pharmaceutical industry shows a possible pathway for lenders.

How banks can appease Trump on credit-card rates

Currently, the cystinosis treatment sector is primarily dominated by traditional cysteamine-based therapies, with minimal access to advanced, curative, or genuinely disease-altering alternatives. Nevertheless, new treatments are starting to revolutionize the field by focusing on...

Unusual Whales

Cystinosis market to grow at 5.1% rate from 2025-2034. Established cysteamine treatments dominate, limited new options.

Merck has partnered with CEPI to enhance the accessibility of its Ebola vaccine, Ervebo, in low-income countries. The $30 million initiative aims to improve manufacturing and distribution, increasing vaccine yield and shelf life. Collaborating with Hilleman Laboratories, the project will also consider differentiated pricing for public-sector buyers. Key improvements include enabling storage in standard refrigerators, facilitating distribution in remote areas. This partnership is part of a global effort to make epidemic vaccines more sustainable and strengthen outbreak response in vulnerable regions.

marketscreener

Merck

Merck: teams up with CEPI to make the Ebola vaccine more accessible in low-income countries

Dublin - The global market for achromatopsia is projected to witness significant growth, with estimations indicating an increase from USD 121.99 million in 2026 to USD 191.22 million by 2032, representing a compound annual growth rate of 7.58%. This growth is attributed to advancements in genetic characterization, diagnostics, and treatment options within the field of achromatopsia. The market landscape for achromatopsia is outlined in a comprehensive research report available on ResearchAndMarkets.com.

Global Achromatopsia Market to reach USD 191.22 million by 2032 with 7.58% CAGR growth, highlights genetic advancements.

ProImmune Ltd has announced the Mastering Immunity 2026 symposium, set for April 13-14, 2026, at the Oriental Riverside Hotel in Shanghai. This inaugural event will focus on immunogenicity challenges in drug development, featuring global leaders in biotherapeutics and regulatory authorities. The symposium aims to provide practical guidance for managing immunogenicity risks, which can significantly impact the success of drug programs. Notable speakers include experts from the FDA, Pfizer, and Roche. The event is positioned as essential for those involved in the biopharmaceutical industry in China.

- ProImmune Ltd is hosting the Mastering Immunity 2026 symposium in Shanghai on April 13-14, 2026, to address immunogenicity challenges in drug development.  
- The event will feature leading experts discussing insights and regulatory perspectives to aid drug developers in managing immunogenicity risks, which can lead to significant financial and developmental setbacks.  
- This initiative supports the rapidly evolving pharmaceutical landscape in China by fostering collaboration among global leaders in biotherapeutics and regulatory affairs.

MorningStar

Roche

iShares Global Healthcare

VanEck Biotech ETF

iShares US Pharma

Invesco Nasdaq Biotechnology ETF

Health Care Select Sector SPDR

iShares Biotechnology ETF

Pfizer

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

Immuneering

VG Health

ProImmune Introduces Mastering Immunity 2026 - Shanghai Symposium to Address Key Immunogenicity Challenges

Researchers have discovered the pathway linking obesity to uncontrolled inflammation, which can lead to serious health issues like diabetes and liver disease. The study highlights the role of the NLRP3 protein complex and the enzyme SAMHD1 in this process. Additionally, new research suggests that messenger RNA could be used to improve embryo attachment in the uterus, potentially offering new treatments for infertility. This involves using lipid nanoparticles to deliver genetic material that enhances the endometrium's ability to support embryo implantation.

Reuters

Health Rounds: How obesity leads to uncontrolled inflammation discovered

Industry ETFs in the U.S. stock market opened almost entirely in decline, with the Biotechnology Index ETF, Consumer Discretionary ETF, and Global Technology Stocks Index ETF down by as much as 2.29%. The Internet Stocks Index ETF, Technology Sector ETF, and Semiconductor ETF fell by as much as 1.82%, while the Energy Sector ETF rose by 0.55%

Direxion S&P Biotech Bull 3X

Proshares UltraShort Nasdaq Biotech

GLXG

Galaxy Payroll pre-market down 15.61%; United Microelectronics pre-market up 14.09%; INVO Fertility pre-market up 405.91%; Icon Energy pre-market up 140.21%; RAPT Therapeutics pre-market up 63.42%

Tracking Unusual Activity

Galaxy Payroll

United Microelectronics

Pre-market hot trades in US stocks: Galaxy Payroll pre-market down 15.61%; United Microelectronics pre-market up 14.09%

ASC37 has shown to have an average observed half-life of around 17 days in head-to-head non-human primate studies, which is 7 times longer than retatrutide. This indicates its potential for once-monthly subcutaneous dosing in humans. Additionally, ASC37 exhibited approximately 5-, 4-, and 4-fold greater in vitro activity compared to other substances.

Direxion Daily LLY Bull 2X Shares

Eli Lilly

Ascletis chooses ASC37, a once-monthly subcutaneously administered peptide agonist, with 17-day half-life, for clinical development.

The 2026 AI Agent Economic Outlook predicts a significant shift from generative AI to agent action capabilities, marking the establishment of the "AI Agent Economy." Key trends include a new research paradigm of "Agent-Wrapping-Agent," a revolution in financial infrastructure from KYC to KYA, and economic model reconstruction to address hidden tax crises in open networks. The report highlights advancements in AI reasoning abilities, enabling complex research tasks and interdisciplinary exploration, exemplified by breakthroughs in protein design and fluid dynamics. The AWA architecture enhances research workflows through multi-agent collaboration and self-improvement mechanisms.

CoinLive

2026 AI Agent Economic Outlook: Reshaping AI Identity and the Flow of Network Value

AIM Vaccine updates on 20-valent pneumococcal polysaccharide conjugate vaccine

AIM ImmunoTech Inc.

AIM IMMUNOTECH INC

AIM Vaccine updates on 20-valent pneumococcal polysaccharide conjugate vaccine

ASBPW

LB filings

ASPIRE BIOPHARMA HOLDINGS INC C/WTS 14/02/2030 (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 1.941 K

ASPIRE BIOPHARMA HOLDINGS INC C/WTS 14/02/2030 (TO PUR COM) | 10-Q: FY2025 Q2 EPS: USD -0.41

ASPIRE BIOPHARMA HOLDINGS INC C/WTS 14/02/2030 (TO PUR COM) | 10-Q: FY2025 Q1 EPS: USD -0.42

ASPIRE BIOPHARMA HOLDINGS INC C/WTS 14/02/2030 (TO PUR COM)(ASBPW.US)

"Wood Sister" Annual Heavyweight: ARK 2026 Big Idea

How banks can appease Trump on credit-card rates

Cystinosis market to grow at 5.1% rate from 2025-2034. Established cysteamine treatments dominate, limited new options.

Merck: teams up with CEPI to make the Ebola vaccine more accessible in low-income countries

Global Achromatopsia Market to reach USD 191.22 million by 2032 with 7.58% CAGR growth, highlights genetic advancements.